Target-to-Lead
In times of increasing financial pressures in the drug discovery industry, a need to improve efficiency is imperative - even in large pharmaceutical companies. Fragment-based lead discovery is an efficient, cost-effective platform for the rapid discovery of potent and selective inhibitors from multiple chemical classes. These compounds are typically low molecular weight with chemical properties consistent with successful clinical candidates.
Target-to-lead services, provides valuable information in advance of committing internal resources or in parallel with an internal high-throughput screening campaign. Feasibility can be assessed and valuable tool compounds for in vivo proof of concept studies can be obtained early in the program before making a significant financial investment. Starting points for lead optimization are also available for rapid lead optimization into clinical candidates with IP or a clear path to IP.
To offer the highest quality target-to-lead services, Zenobia has partnered with BioBlocks, Inc a leader in collaborative medicinal chemistry.
This partnership combines BioBlocks medicinal chemistry expertise with Zenobia's expertise in structural biology and fragment-based lead discovery. BioBlocks unique collection of building blocks also form the basis for a new joint fragment library that includes existing compounds and synthetic compounds designed to better cover functional group diversity space in addition to core diversity space. This joint library was also prepared to enable rapid synthetic follow-up of fragment hits using BioBlocks existing synthetic protocols.
Target-to-lead services, provides valuable information in advance of committing internal resources or in parallel with an internal high-throughput screening campaign. Feasibility can be assessed and valuable tool compounds for in vivo proof of concept studies can be obtained early in the program before making a significant financial investment. Starting points for lead optimization are also available for rapid lead optimization into clinical candidates with IP or a clear path to IP.
To offer the highest quality target-to-lead services, Zenobia has partnered with BioBlocks, Inc a leader in collaborative medicinal chemistry.
This partnership combines BioBlocks medicinal chemistry expertise with Zenobia's expertise in structural biology and fragment-based lead discovery. BioBlocks unique collection of building blocks also form the basis for a new joint fragment library that includes existing compounds and synthetic compounds designed to better cover functional group diversity space in addition to core diversity space. This joint library was also prepared to enable rapid synthetic follow-up of fragment hits using BioBlocks existing synthetic protocols.
